Castle Biosciences is a leading diagnostics company improving health through innovative tests that guide patient care. We aim to transform disease management by keeping people first and are committed to empowering healthcare providers and patients with the goal of improved health outcomes. Primarily focused on dermatologic cancers and gastroenterological disease, our innovative tests are designed to help answer critical clinical questions and address treatment plan challenges facing clinicians to better inform patient care decisions.

TissueCypher® Barrett’s Esophagus is a precision medicine test that can predict the future development of high-grade dysplasia and/or esophageal cancer in patients with Barrett’s esophagus. TissueCypher is used in patients with Barrett’s esophagus that are graded non-dysplastic, indefinite for dysplasia or low-grade dysplasia. The test provides a five-year risk of progression to high-grade dysplasia or esophageal adenocarcinoma. TissueCypher’s clinical performance has been supported by 14 peer-reviewed publications with leading clinical centers around the world and is recognized by the 2022 American Gastroenterological Association’s Clinical Practice Update as a tool that may be used to risk-stratify patients with non-dysplastic Barrett’s esophagus.

To learn more visit  www.CastleBiosciences.com.